Evaxion Biotech AS (Evaxion Biotech AS) LT-Debt-to-Total-Asset : 0.81 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Evaxion Biotech AS's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.81.

Evaxion Biotech AS's long-term debt to total assets ratio increased from Dec. 2022 (0.45) to Dec. 2023 (0.81). It may suggest that Evaxion Biotech AS is progressively becoming more dependent on debt to grow their business.

Evaxion Biotech AS LT-Debt-to-Total-Asset Historical Data

The historical data trend for Evaxion Biotech AS's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS LT-Debt-to-Total-Asset Chart

Evaxion Biotech AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.08

0.45

0.81

Evaxion Biotech AS Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial														0.45	-	0.60	-	0.81

Evaxion Biotech AS LT-Debt-to-Total-Asset Calculation

Evaxion Biotech AS's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	10.385	/	12.889
	=	0.81

Evaxion Biotech AS's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	10.385	/	12.889
	=	0.81

Evaxion Biotech AS (NAS:EVAX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Evaxion Biotech AS LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS (Evaxion Biotech AS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970

Website

https://www.evaxion-biotech.com

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.